What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60”In the company’s words, NCT07298434 on ClinicalTrials.gov
- Tested for
- COVID-19 (2 trials), Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine, COVID Long
- Main trialPhase 3
- “The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study.…”In the company’s words, NCT07298434 on ClinicalTrials.gov
Other drugs for COVID-19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
- DAS181Ansun Biopharma, Inc. · Phase 3
Coming up1
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Aug 2026 | Study of VYD2311 for the Prevention of COVID-19 | |
| Phase 2Not yet recruiting | Jun 2027 | Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome | |
| Phase 1Active, not recruiting | May 2025 | A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants | |
| Phase 3Completed | 15 Aug 2026 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026